Literature DB >> 20679525

Closed headpiece of integrin αIIbβ3 and its complex with an αIIbβ3-specific antagonist that does not induce opening.

Jieqing Zhu1, Jianghai Zhu, Ana Negri, Davide Provasi, Marta Filizola, Barry S Coller, Timothy A Springer.   

Abstract

The platelet integrin α(IIb)β(3) is essential for hemostasis and thrombosis through its binding of adhesive plasma proteins. We have determined crystal structures of the α(IIb)β(3) headpiece in the absence of ligand and after soaking in RUC-1, a novel small molecule antagonist. In the absence of ligand, the α(IIb)β(3) headpiece is in a closed conformation, distinct from the open conformation visualized in presence of Arg-Gly-Asp (RGD) antagonists. In contrast to RGD antagonists, RUC-1 binds only to the α(IIb) subunit. Molecular dynamics revealed nearly identical binding. Two species-specific residues, α(IIb) Y190 and α(IIb) D232, in the RUC-1 binding site were confirmed as important by mutagenesis. In sharp contrast to RGD-based antagonists, RUC-1 did not induce α(IIb)β(3) to adopt an open conformation, as determined by gel filtration and dynamic light scattering. These studies provide insights into the factors that regulate integrin headpiece opening, and demonstrate the molecular basis for a novel mechanism of integrin antagonism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20679525      PMCID: PMC3012599          DOI: 10.1182/blood-2010-04-281154

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists.

Authors:  L K Jennings; J H Haga; S M Slack
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

2.  Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.

Authors:  D P Chew; D L Bhatt; S Sapp; E J Topol
Journal:  Circulation       Date:  2001-01-16       Impact factor: 29.690

Review 3.  Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents.

Authors:  R M Scarborough; D D Gretler
Journal:  J Med Chem       Date:  2000-09-21       Impact factor: 7.446

4.  Well-tempered metadynamics: a smoothly converging and tunable free-energy method.

Authors:  Alessandro Barducci; Giovanni Bussi; Michele Parrinello
Journal:  Phys Rev Lett       Date:  2008-01-18       Impact factor: 9.161

Review 5.  Drug-induced immune thrombocytopenia.

Authors:  Richard H Aster; Daniel W Bougie
Journal:  N Engl J Med       Date:  2007-08-09       Impact factor: 91.245

6.  Structure of integrin alpha5beta1 in complex with fibronectin.

Authors:  Junichi Takagi; Konstantin Strokovich; Timothy A Springer; Thomas Walz
Journal:  EMBO J       Date:  2003-09-15       Impact factor: 11.598

7.  A novel regulatory epitope defined by a murine monoclonal antibody to the platelet GPIIb-IIIa complex (alpha IIb beta 3 integrin).

Authors:  M Tokuhira; M Handa; T Kamata; A Oda; M Katayama; Y Tomiyama; M Murata; Y Kawai; K Watanabe; Y Ikeda
Journal:  Thromb Haemost       Date:  1996-12       Impact factor: 5.249

8.  Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa.

Authors:  Daniel W Bougie; Peter R Wilker; Elizabeth D Wuitschick; Brian R Curtis; Mohammad Malik; Stewart Levine; Richard N Lind; Jaime Pereira; Richard H Aster
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

9.  Structural and therapeutic insights from the species specificity and in vivo antithrombotic activity of a novel alphaIIb-specific alphaIIbbeta3 antagonist.

Authors:  Robert Blue; M Anna Kowalska; Jessica Hirsch; Marta Murcia; Christin A Janczak; Amanda Harrington; Marketa Jirouskova; Jihong Li; Rudy Fuentes; Michael A Thornton; Marta Filizola; Mortimer Poncz; Barry S Coller
Journal:  Blood       Date:  2009-05-04       Impact factor: 22.113

10.  Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

Authors:  Cunji Gao; Brian Boylan; Dan Bougie; Joan C Gill; Jessica Birenbaum; Debra K Newman; Richard H Aster; Peter J Newman
Journal:  J Clin Invest       Date:  2009-02-09       Impact factor: 14.808

View more
  55 in total

1.  New platelet glycoprotein polymorphisms causing maternal immunization and neonatal alloimmune thrombocytopenia.

Authors:  Julie A Peterson; Shannon M Pechauer; Maria L Gitter; Adam Kanack; Brian R Curtis; Jeff Reese; Vasudeva M Kamath; Janice G McFarland; Richard H Aster
Journal:  Transfusion       Date:  2011-11-09       Impact factor: 3.157

2.  Small molecule agonist of very late antigen-4 (VLA-4) integrin induces progenitor cell adhesion.

Authors:  Peter Vanderslice; Ronald J Biediger; Darren G Woodside; Wells S Brown; Sayadeth Khounlo; Navin D Warier; C William Gundlach; Amy R Caivano; William G Bornmann; David S Maxwell; Bradley W McIntyre; James T Willerson; Richard A F Dixon
Journal:  J Biol Chem       Date:  2013-05-23       Impact factor: 5.157

3.  Intact alphaIIbbeta3 integrin is extended after activation as measured by solution X-ray scattering and electron microscopy.

Authors:  Edward T Eng; Benoit J Smagghe; Thomas Walz; Timothy A Springer
Journal:  J Biol Chem       Date:  2011-08-09       Impact factor: 5.157

4.  Structural and functional aspects of decorsin and its analog as recognized by integrin αIIbβ3.

Authors:  Xingzhen Lao; Jingxiao Bao; Tingting Yu; Qingqing Li; Heng Zheng
Journal:  J Mol Model       Date:  2016-10-29       Impact factor: 1.810

5.  Autonomous conformational regulation of β3 integrin and the conformation-dependent property of HPA-1a alloantibodies.

Authors:  Aye Myat Myat Thinn; Zhengli Wang; Dongwen Zhou; Yan Zhao; Brian R Curtis; Jieqing Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-12       Impact factor: 11.205

6.  Structure-guided design of a high-affinity platelet integrin αIIbβ3 receptor antagonist that disrupts Mg²⁺ binding to the MIDAS.

Authors:  Jieqing Zhu; Won-Seok Choi; Joshua G McCoy; Ana Negri; Jianghai Zhu; Sarasija Naini; Jihong Li; Min Shen; Wenwei Huang; Daniel Bougie; Mark Rasmussen; Richard Aster; Craig J Thomas; Marta Filizola; Timothy A Springer; Barry S Coller
Journal:  Sci Transl Med       Date:  2012-03-14       Impact factor: 17.956

Review 7.  Integrin αIIbβ3: from discovery to efficacious therapeutic target.

Authors:  Kamila Bledzka; Susan S Smyth; Edward F Plow
Journal:  Circ Res       Date:  2013-04-12       Impact factor: 17.367

8.  Small molecule agonists of integrin CD11b/CD18 do not induce global conformational changes and are significantly better than activating antibodies in reducing vascular injury.

Authors:  Mohd Hafeez Faridi; Mehmet M Altintas; Camilo Gomez; Juan Camilo Duque; Roberto I Vazquez-Padron; Vineet Gupta
Journal:  Biochim Biophys Acta       Date:  2013-02-26

9.  The platelet: life on the razor's edge between hemorrhage and thrombosis.

Authors:  Barry S Coller
Journal:  Transfusion       Date:  2014-08-05       Impact factor: 3.157

10.  Structural basis for quinine-dependent antibody binding to platelet integrin αIIbβ3.

Authors:  Jianghai Zhu; Jieqing Zhu; Daniel W Bougie; Richard H Aster; Timothy A Springer
Journal:  Blood       Date:  2015-08-17       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.